Krystal Biotech (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $358.24 on Friday. Krystal Biotech, Inc. has a 52-week low of $136.73 and a 52-week high of $382.54. The firm has a market cap of $10.60 billion, a price-to-earnings ratio of 44.89 and a beta of 0.54. The business’s fifty day moving average is $349.81 and its 200 day moving average is $307.38.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Equities analysts predict that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Silvant Capital Management LLC bought a new stake in shares of Krystal Biotech during the 2nd quarter worth $30,000. Western Wealth Management LLC bought a new position in Krystal Biotech in the first quarter valued at $34,000. Greenline Wealth Management LLC bought a new position in Krystal Biotech in the fourth quarter valued at $34,000. UMB Bank n.a. increased its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

KRYS has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada initiated coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 price target for the company. Weiss Ratings cut Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Finally, Citigroup lifted their price target on Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.